Cargando…

GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival

The use of mutant strains of oncolytic herpes simplex virus (oHSV) in early-phase human clinical trials for the treatment of glioblastoma multiforme (GBM) has proven safe, but limited efficacy suggests that more potent vector designs are required for effective GBM therapy. Inadequate vector performa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sette, Paola, Amankulor, Nduka, Li, Aofei, Marzulli, Marco, Leronni, Daniela, Zhang, Mingdi, Goins, William F., Kaur, Balveen, Bolyard, Chelsea, Cripe, Timothy P., Yu, Jianhua, Chiocca, E. Antonio, Glorioso, Joseph C., Grandi, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926261/ https://www.ncbi.nlm.nih.gov/pubmed/31890868 http://dx.doi.org/10.1016/j.omto.2019.10.005

Ejemplares similares

Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment
por: Jackson, Joseph W., et al.
Publicado: (2021)

IM-4 Impact of oHSV activated NOTCH signaling in tumor microenvironment and its impact on anti-tumor immunity
por: Yoshihiro, Otani, et al.
Publicado: (2021)

oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy
por: Sahu, Upasana, et al.
Publicado: (2023)

Novel mutations in U(L)24 and gH rescue efficient infection of an HSV vector retargeted to TrkA
por: Marzulli, Marco, et al.
Publicado: (2023)

esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation
por: Swanner, Jessica, et al.
Publicado: (2023)

Expression of HSV-1 Receptors in EBV-Associated Lymphoproliferative Disease Determines Susceptibility to Oncolytic HSV
por: Wang, Pin-Yi, et al.
Publicado: (2012)

Detection of circulating tumor cells using oHSV1‐hTERT‐GFP in lung cancer
por: Gao, Hongjun, et al.
Publicado: (2017)

STING Restricts oHSV Replication and Spread in Resistant MPNSTs but Is Dispensable for Basal IFN-Stimulated Gene Upregulation
por: Lee, Joel M., et al.
Publicado: (2019)

Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV
por: Vannini, Andrea, et al.
Publicado: (2021)

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV
por: Gianni, Tatiana, et al.
Publicado: (2021)

Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors
por: Abdoli, Shahriyar, et al.
Publicado: (2017)

Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity
por: Leddon, Jennifer L, et al.
Publicado: (2015)

oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity
por: Zhang, Wen, et al.
Publicado: (2020)

STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells
por: Okemoto, Kazuo, et al.
Publicado: (2013)

Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRα1 for Specific Infection of Breast Cancer Cells
por: Hall, Bonnie L., et al.
Publicado: (2020)

A novel oHSV-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4
por: Zhang, Wen, et al.
Publicado: (2015)

A Novel Oncolytic Herpes Simplex Virus Design based on the Common Overexpression of microRNA-21 in Tumors
por: Marzulli, M, et al.
Publicado: (2018)

USP18 and USP20 restrict oHSV-1 replication in resistant human oral squamous carcinoma cell line SCC9 and affect the viability of SCC9 cells
por: Lu, Ruitao, et al.
Publicado: (2021)

Therapeutic Application of Brain-Specific Angiogenesis Inhibitor 1 for Cancer Therapy
por: Nair, Mitra, et al.
Publicado: (2021)

MnSOD mediated by HSV vectors in the periaqueductal gray suppresses morphine withdrawal in rats
por: Iida, Takafumi, et al.
Publicado: (2017)

Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line
por: Vannini, Andrea, et al.
Publicado: (2021)

Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles
por: Fu, Xinping, et al.
Publicado: (2018)

An HSV-based library screen identifies PP1α as a negative TRPV1 regulator with analgesic activity in models of pain
por: Reinhart, Bonnie, et al.
Publicado: (2016)

Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes
por: Miyagawa, Yoshitaka, et al.
Publicado: (2017)

Protocol Optimization for the Production of the Non-Cytotoxic JΔNI5 HSV Vector Deficient in Expression of Immediately Early Genes
por: Kuroda, Seiji, et al.
Publicado: (2020)

Dissecting the tumor microenvironment of epigenetically driven gliomas: Opportunities for single-cell and spatial multiomics
por: Sussman, Jonathan H, et al.
Publicado: (2023)

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
por: Han, Jianfeng, et al.
Publicado: (2015)

HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
por: Koch, Marilin S., et al.
Publicado: (2020)

Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells
por: Alvarez-Breckenridge, Christopher A., et al.
Publicado: (2012)

HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain
por: Hao, Shuanglin, et al.
Publicado: (2006)

Engineered HSV vector achieves safe long-term transgene expression in the central nervous system
por: Verlengia, Gianluca, et al.
Publicado: (2017)

The dominant TP53 hotspot mutation in IDH-mutant astrocytoma, R273C, has distinctive pathologic features and sex-specific prognostic implications
por: Marker, Daniel F, et al.
Publicado: (2021)

Anti-GBM-Nephritis
por: Windpessl, Martin, et al.
Publicado: (2023)

Fully automatic GBM segmentation in the TCGA-GBM dataset: Prognosis and correlation with VASARI features
por: Rios Velazquez, Emmanuel, et al.
Publicado: (2015)

Differentiation of Human GBM From Non-GBM Brain Tissue With Polarization Imaging Technique
por: Liu, Yi-Rong, et al.
Publicado: (2022)

Astrocyte-Specific Expression Patterns Associated with the PDGF-Induced Glioma Microenvironment
por: Katz, Amanda M., et al.
Publicado: (2012)

Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells
por: Mukherjee, Sumit, et al.
Publicado: (2018)

Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII bearing tumor cells
por: Grandi, Paola, et al.
Publicado: (2010)

Advances in nanotechnology for the treatment of GBM
por: Wei, Dongyan, et al.
Publicado: (2023)

Anti-GBM disease with a mild relapsing course and low levels of anti-GBM autoantibodies
por: Segelmark, Mårten, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2s8554uusv7lhk5mrhkcb4ghbg